Continued access to fedratinib for former trial participants
Part of Blood & lymphatic clinical trials.
This program provides continued access to the study drug fedratinib for people who previously received it in a clinical trial before January 31, 2018. It ensures you can keep taking the medication if you benefited from it and no other trial is available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took part in a clinical trial and received the study drug (fedratinib or its earlier versions) before January 31, 2018.
- You are not currently eligible for another ongoing clinical trial that uses fedratinib.
- You have not taken fedratinib after January 31, 2018.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called revumenib, which is being studied for people with myelofibrosis. Revumenib may help slow the disease and improve symptoms. The study has two parts: one for people who have already tried a JAK inhibitor, and one for those currently on a JAK inhibitor but still have active disease.
This trial tests an oral medicine called flonoltinib maleate for people with myelofibrosis. It may help reduce an enlarged spleen and improve symptoms like fatigue and night sweats.
This trial tests a combination of two oral medications for people with myelofibrosis, a type of bone marrow cancer. It may be an option if you have not been helped by standard JAK inhibitor therapy or if you have never tried one.
This trial tests an oral drug called tasquinimod for people with myelofibrosis that no longer responds to or cannot take a JAK inhibitor. The goal is to see if tasquinimod can help shrink an enlarged spleen and improve symptoms.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
This study looks at how well pacritinib works in everyday medical practice for people with myelofibrosis, a type of bone marrow disorder. It helps us understand the benefits and risks of this treatment for patients like you.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.